Navigation Links
MD Anderson, Foundation Medicine, team up to improve targeted therapies in metastatic disease

The University of Texas MD Anderson Cancer Center announced today an alliance with Cambridge, MA-based Foundation Medicine. The teams are opening a randomized-controlled trial to determine whether targeted therapies selected based on tumor molecular profiling compared with treatment not selected on this basis results in longer progression-free survival in patients with advanced disease.

This study aims to demonstrate that targeted therapies matched to individual patients can improve outcomes. This would support the broader use of this therapeutic strategy across all types of cancers, not just in select ones for whom existing diagnostic and treatment options were insufficient.

Known as the IMPACT2 (Initiative for Molecular Profiling and Advanced Cancer Therapy) trial, the study builds on promising results from the first IMPACT trial, presented at the American Society of Clinical Oncology's Annual Meeting in 2011.

That previous study found that of the 1,144 patients enrolled, 40 percent had an identifiable genomic alteration. This early data enabled numerous cancer centers and practicing oncologists to begin using this approach as standard practice to benefit select groups of metastatic patients for whom targeted therapies were medically necessary.

By matching specific gene alterations to therapies, 27 percent of patients responded, compared to 5 percent with an unmatched treatment, and progression-free survival was appreciably longer in the matched group.

Led by Apostolia Maria Tsimberidou, M.D., Ph.D., the IMPACT2 study is an effort to further validate the earlier findings and results of non-randomized studies while engaging industry leaders in genomic profiling. Recognized as precision medicine, MD Anderson physician-scientists believe the approach will lend itself to better patient outcomes. It will also help match patients for clinical trials of new medications, as well as reduce the cost and time necessary to conduct those trials.

"This is a collaborative and institutional-wide effort to improve patient care and accelerate the drug development process," Tsimberidou said. "If the results of IMPACT1 are confirmed, cancer treatment will be transformed and comprehensive molecular profiling will become the standard of care."

The trial is made possible through collaboration with Foundation Medicine, which will provide support with their validated, comprehensive genomic profiling assay, FoundationOne, which detects all classes of genomic alterations in solid tumors across 315 cancer-related genes, as well as 28 other genes often rearranged in cancer. It's expected that more patients will be eligible for targeted therapies given the more comprehensive nature of FoundationOne versus the molecular testing used in IMPACT1.

"Based on the IMPACT1 data, a validated, comprehensive profiling approach has already been adopted by many academic and community-based oncology practices. They use this approach for select groups of cancer patients for whom existing diagnostic and treatment options are inadequate, such as non-small cell lung cancer, cancer of unknown primary and rare tumors," said Vincent Miller, M.D., chief medical officer of Foundation Medicine. "This study has the potential to yield sufficient evidence necessary to support broader adoption across most newly diagnosed metastatic tumors. We're pleased to partner with MD Anderson, who is uniquely positioned to execute this study given their clinical trials expertise."

The effort brings together MD Anderson's capabilities from several departments, including Investigational Cancer Therapeutics, Thoracic/Head and Neck Medical Oncology, Genitourinary Medical Oncology, Melanoma Medical Oncology, Sarcoma Medical Oncology, Gynecologic Oncology, and Endocrine Neoplasia and Hormonal Disorders; and from several divisions, including Diagnostic Imaging, Pathology, Surgical Oncology, and Biostatistics. Physicians and researchers will be able to select eligible patients who may benefit and contribute to all aspects of the study.

Information derived from tumor profiling will be available three weeks from the start of enrollment to guide treatment decisions.

"We're pleased to collaborate with Dr. Tsimberidou and MD Anderson on this important clinical trial that's bringing the benefits of FoundationOne to patients with cancer," said Michael J. Pellini, M.D., president and CEO of Foundation Medicine. "This trial, and others like it, are helping to drive the oncology field forward at a pace never seen before, supporting the evaluation and development of targeted therapies. It will ultimately help to provide safer and more effective treatments for all patients with cancer."

"Through this effort we're partnering with a leader in genomic testing and analysis to further demonstrate how tumor profiling has the potential to improve therapies and reduce development costs," said Ferran Prat, Ph.D., J.D. and vice president of MD Anderson's Strategic Industry Ventures.


Contact: William Fitzgerald
University of Texas M. D. Anderson Cancer Center

Related medicine news :

1. UT MD Anderson, GlaxoSmithKline to collaborate on new approach to cancer immune therapy
2. Dr. James Sanderson, Jr. Of SanDentistry in Hoover, Alabama Joins the Family
3. Sleep Apnea Treatment Becoming More Popular in New York After Long Island Dental Sleep Medicine Begins Treatment on OJ Anderson, Giants Super Bowl Champion
4. MD Anderson, MedImmune join forces to advance cancer immunotherapy
5. Kessler Foundation names Dr. John Whyte recipient of Foundations 2nd Annual DeLisa Award
6. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
7. Kessler Foundation researchers present at first International Congress on Cognition in MS
8. Biomedical researchers receive Hartwell Foundation awards
9. Kessler Foundation scientists present cognitive research findings at MS dual symposium
10. Damon Runyon Cancer Research Foundation awards $3.3 million to 8 top young clinical investigators
11. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
Post Your Comments:
Related Image:
MD Anderson, Foundation Medicine, team up to improve targeted therapies in metastatic disease
(Date:11/25/2015)... Cleveland, OH (PRWEB) , ... November 25, 2015 , ... ... dental implants in Cleveland, OH , are invited to attend Dr. Mark Iacobelli’s Advanced ... 5th this year in Cleveland, OH. , As the co-founders of Advanced Implant ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law ... successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys ... Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock ...
(Date:11/25/2015)... ... ... SCOTTSDALE, AZ) - Today, Dr. Todd C. Hobgood ... non-surgical treatments, announced the expansion of his private practice capabilities with the grand ... trained and nationally recognized for his natural approach, Dr. Todd Hobgood serves the ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... ... November 25, 2015 , ... Castlewood ... people struggling with eating disorders as a result of the $20,000 raised at ... held at Fox Run Golf Club in Eureka, will help individuals who otherwise ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
(Date:11/25/2015)... Kitov Pharma ceuticals ... biopharmaceutical company focused on the development of therapeutic candidates ... announced the closing of its previously announced underwritten public ... each representing 20 ordinary shares of the Company, and ... and warrants were issued in a fixed combination of ...
(Date:11/25/2015)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer of ... Antonius Schuh, Ph.D., is scheduled to present a corporate ... Healthcare Conference. th Annual Piper Jaffray ... New York on Tuesday, December ... be available for one-on-one meetings during the conference. The ...
Breaking Medicine Technology: